AMG 487 (Synonyms: (±)-AMG 487) |
Catalog No.GC11939
One-Click Copy Product Info
|
AMG 487 is an oral, selective chemokine receptor 3 (CXCR3) antagonist that inhibits CXCL10 and CXCL11 binding to CXCR3 with IC50 values of 8.0 and 8.2 nM, respectively.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 473719-41-4
Sample solution is provided at 25 µL, 10mM.
AMG 487 is an oral, selective chemokine receptor 3 (CXCR3) antagonist that inhibits CXCL10 and CXCL11 binding to CXCR3 with IC50 values of 8.0 and 8.2 nM, respectively[1].
AMG 487(1 µM AMG 487;18 h (C26 cells) or 40 h (HT29 cells)), the CXCR3 antagonist, significantly inhibited the migratory responses of the cells to each of the three ligands(rCXCL9, rCXCL10 and rCXCL11)[2].
the AMG 487-treated mice(SCID mice:1 µM AMG 487;s.c.7-17day. Balb/c mice:5 mg/kg: s.c.˙twice daily.) exhibited fewer pulmonary nodules than the control mice in both the models: a 62% reduction in the human mode and 42% less nodules in the mouse model. The inhibitory effect of AMG 487 treatment was also detectable in the cumulative tumour volume with a reduction by 58% in the lungs of the HT29-injected immunodeficient mice and by 51% in the lungs of the C26-injected syngeneic mice[2]. During in vitro differentiation, the addition of AMG 487(3- 60µM) decreased the expression of DC co-stimulatory markers, indicating that DC was in a semi-mature state[4]. 66.1 tumor cells were pretreated with AMG 487 prior to i.v. injection into immune-competent female mice. Antagonism of CXCR3 on 66.1 tumor cells inhibited experimental lung metastasis, and this antimetastatic activity was compromised in mice depleted of natural killer cells. Systemic administration of AMG 487(5 mg/kg;s.c.;twice daily) also inhibited experimental lung metastasis[3]. In mice, injection of AMG-487 (i.c.v.)significantly attenuated the accumulation of c-fos in neurons induced by polyinosinic-polycytidylic acid (PIC)[5]. WT mice treated with AMG-487 (5 µg/g twice a day) showed a 45% reduction in bone loss and decreased osteoclasts after LPS injections[6]. Meanwhile, AMG 487 treatment significantly reduced bone loss in mice[7].
References:
[1]. Johnson M, Li AR,et,al. Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3. Bioorg Med Chem Lett. 2007 Jun 15;17(12):3339-43. doi: 10.1016/j.bmcl.2007.03.106. Epub 2007 Apr 6. PMID: 17448658.
[2]. Cambien B, Karimdjee BF, et,al. Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism. Br J Cancer. 2009 Jun 2;100(11):1755-64. doi: 10.1038/sj.bjc.6605078. Epub 2009 May 12. PMID: 19436305; PMCID: PMC2695685.
[3]. Walser TC, Rifat S, et,al. Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res. 2006 Aug 1;66(15):7701-7. doi: 10.1158/0008-5472.CAN-06-0709. PMID: 16885372.
[4]. Qin C, Liu H, et,al.In Vitro Immunological Effects of CXCR3 Inhibitor AMG487 on Dendritic Cells. Arch Immunol Ther Exp (Warsz). 2020 Apr 1;68(2):11. doi: 10.1007/s00005-020-00577-3. PMID: 32239302.
[5]. Petrisko TJ, Konat GW. Peripheral viral challenge increases c-fos level in cerebral neurons. Metab Brain Dis. 2021 Oct;36(7):1995-2002. doi: 10.1007/s11011-021-00819-z. Epub 2021 Aug 18. PMID: 34406561.
[6]. Hiyari S, Green E, et,al. Genomewide Association Study Identifies Cxcl Family Members as Partial Mediators of LPS-Induced Periodontitis. J Bone Miner Res. 2018 Aug;33(8):1450-1463. doi: 10.1002/jbmr.3440. Epub 2018 May 22. PMID: 29637625; PMCID: PMC8434897.
[7]. Lari S, Hiyari S, et,al. Local delivery of a CXCR3 antagonist decreases the progression of bone resorption induced by LPS injection in a murine model. Clin Oral Investig. 2022 Aug;26(8):5163-5169. doi: 10.1007/s00784-022-04484-z. Epub 2022 Apr 25. PMID: 35462591; PMCID: PMC9710470.
| Cell experiment [1]: | |
|
Cell lines |
C26 cells and HT29 cells |
|
Preparation Method |
Cells treated or not with 1 µM AMG487 or dimethyl sulfoxide (DMSO) vehicle were placed in the upper well and various concentrations of human or mouse rCXCL9, rCXCL10 and rCXCL11 were added to the lower wells. After incubation of the plates for 18 h (C26 cells) or for 40 h (HT29 cells) at 37 C in 5% CO2 atmosphere, non-migrated cells were removed from the upper well and the migrated cells collected on the lower side of the insert were stained using crystal violet dye and enumerated. |
|
Reaction Conditions |
1 µM AMG487;18 h (C26 cells) or 40 h (HT29 cells) |
|
Applications |
AMG 487, the CXCR3 antagonist, significantly inhibited the migratory responses of the cells to each of the three ligands(rCXCL9, rCXCL10 and rCXCL11). |
| Animal experiment [1]: | |
|
Animal models |
SCID and Balb/c mice |
|
Preparation Method |
For the induction of pulmonary metastases, HT29 cells or C26 cells were delivered by intravenous tail injection into SCID or Balb/c mice, respectively. For the polymetastatic liver model, HT29 cells or C26 cells were injected intravenously into the portal vein of Nude or Balb/c mice, respectively. The curative treatment of the mice-bearing metastases was achieved by treating the animals twice daily on days +5 to +12 (syngeneic C26 model) or on days +5 to +23 (immunodeficient HT29 model) with subcutaneous injections of 5 mg/kg of AMG 487 or vehicle. The preventive treatment to antagonise CXCR3 was performed by incubating the colon cancer cells with 1 µM of AMG 487 or vehicle for 18 h in vitro before their injection into mice and by treating concomitantly the animals twice daily on days 1 and 0 with subcutaneous injections of 5 mg/kg of AMG487 or vehicle. |
|
Dosage form |
SCID :1 µM AMG 487;s.c.7-17day. |
|
Applications |
The AMG 487-treated mice exhibited fewer pulmonary nodules than the control mice in both the models: a 62% reduction in the human mode and 42% less nodules in the mouse model. The inhibitory effect of AMG 487 treatment was also detectable in the cumulative tumour volume with a reduction by 58% in the lungs of the HT29-injected immunodeficient mice and by 51% in the lungs of the C26-injected syngeneic mice. |
|
References: |
|
| Cas No. | 473719-41-4 | SDF | |
| Synonyms | (±)-AMG 487 | ||
| Chemical Name | N-[(1R)-1-[3-(4-ethoxyphenyl)-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-N-(pyridin-3-ylmethyl)-2-[4-(trifluoromethoxy)phenyl]acetamide | ||
| Canonical SMILES | CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(C=C5)OC(F)(F)F | ||
| Formula | C32H28F3N5O4 | M.Wt | 603.59 |
| Solubility | ≥ 122.2 mg/mL in DMSO, ≥ 122 mg/mL in EtOH | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.6568 mL | 8.2838 mL | 16.5675 mL |
| 5 mM | 331.4 μL | 1.6568 mL | 3.3135 mL |
| 10 mM | 165.7 μL | 828.4 μL | 1.6568 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 40 reference(s) in Google Scholar.)